Compare GAUZ & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAUZ | PBYI |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 263.4M |
| IPO Year | 2024 | N/A |
| Metric | GAUZ | PBYI |
|---|---|---|
| Price | $1.06 | $5.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.50 | $7.00 |
| AVG Volume (30 Days) | 327.3K | ★ 398.8K |
| Earning Date | 03-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | $96,810,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $22.59 | N/A |
| Revenue Next Year | $47.83 | N/A |
| P/E Ratio | ★ N/A | $7.56 |
| Revenue Growth | ★ 7.87 | N/A |
| 52 Week Low | $0.95 | $2.58 |
| 52 Week High | $13.00 | $6.12 |
| Indicator | GAUZ | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 28.61 | 63.95 |
| Support Level | $0.95 | $5.51 |
| Resistance Level | $1.57 | $5.73 |
| Average True Range (ATR) | 0.27 | 0.23 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 6.69 | 93.15 |
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.